bioidentical hormones are again in jeopardy of becoming inaccessible. In
2007, American women successfully blocked the FDA proposed ban on compounded
estriol, with an overwhelming number of communications to Congress. Now we need your help to achieve this level of
FDA recently tasked and funded the National Academies of Science, Engineering,
and Medicine (NASEM) to evaluate the “clinical utility” of compounded
BHRT. NASEM has conducted several public meetings to date on compounded
BHRT. The Committee designated experts
to present to the NASEM panel.
many hours of testimony before the Committee were assigned to presenters who
either oppose compounding and bioidentical hormone therapy entirely, or who
represented uncommon (and therefore suspect) administration methods of
compounded bioidentical hormone therapy.
Rosensweet, M.D., is a BHRT expert and advocate. During one of the meetings, he was allowed to
present— for just five minutes. Even in
such a short time, Dr. Rosensweet was able to offer compelling evidence for the
value and uses of compounded BHRT.
Rosensweet’s opinion is that the NASEM Committee members lack a fundamental
understanding of how compounded BHRT is properly used to treat menopause. Lack of knowledge and experience leaves
Committee members vulnerable to the torrent of misinformation and bias that
they have received.
must get Dr. Rosensweet more time to present to the NASEM Committee. Approximately 2.5 million women benefit from
compounded BHRT annually, accounting for one half of all women who are
being treated with hormones in menopause.
We must stop the FDA from plowing forward unchecked, and restricting or
even eliminating our access to compounded bioidentical hormones.
Please let Dr. Rosensweet present on bioidentical hormones
Dear [Decision Maker],
Sincerely,[Your Name] [Your Address] [City, State ZIP][Your Email]